Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q1 2014 · 10-Q
Revenue$1.29M$1.29M+16.8% vs Q1 2013 Net Income-$762.10K-$762.10KN/M vs Q1 2013 EPS Diluted-$0.04-$0.04N/M vs Q1 2013 Gross Profit$728,017+11.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flow$226,727+3,388.6% Margins · derivedGross margin56.5%−2.6 pt vs Q1 2013
Operating margin-59.1%−68.2 pt vs Q1 2013
Net margin-59.1%−38.8 pt vs Q1 2013
ended Mar 31, 2014 · filed May 15, 2014 · 45 d after period end